ImaRx
Proposed symbol IMRX
IPO date not yet announced
ImaRx is a biopharmaceutical company which specializes in developing therapies for vascular disorders, particularly those relating to blood clots. Its SonoLysis therapy uses tiny ultrasound-activated bubbles to penetrate a blood clot and break it up; the company is developing SonoLysis as a stand-alone therapy and in combination with clot-busting drugs. The company has licensing deals with UNEMED and Bristol Myers Squibb for some of the technologies undergirding SonoLyse. ImaRx acquired FDA-approved Abbokinase, which dissolves blood clots in the lungs, from Abbott Laboratories in 2006.
Proposed symbol IMRX
IPO date not yet announced
ImaRx is a biopharmaceutical company which specializes in developing therapies for vascular disorders, particularly those relating to blood clots. Its SonoLysis therapy uses tiny ultrasound-activated bubbles to penetrate a blood clot and break it up; the company is developing SonoLysis as a stand-alone therapy and in combination with clot-busting drugs. The company has licensing deals with UNEMED and Bristol Myers Squibb for some of the technologies undergirding SonoLyse. ImaRx acquired FDA-approved Abbokinase, which dissolves blood clots in the lungs, from Abbott Laboratories in 2006.
Labels: biotech, biotech investing, biotech ipo, biotech mill rumor
posted by doublezero at
2:16 PM
1 Comments:
epicresearch.co Stock Cash call : SELL BIOCON BELOW 466 TARGET 462.25 / 457.60 / 451.80 SL 471.15
Post a Comment
Subscribe to Post Comments [Atom]
<< Home